Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Sponsor
Clinique Neuro-Outaouais
Study ID
NCT06765161
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Myasthaenia Gravis

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • efgartigimod administration — DRUG
    efgartigimod infusion

Study Details

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.

Key Dates

Start date
Feb 6, 2025
Status verified
Jul 2025
Primary completion
Jan 6, 2027
Completion
Jan 6, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment
    Efgartigimod infusion

Primary Outcome Measure

MG-ADL [ Time Frame: a sustained decrease persistent for at least 4 consecutive weeks over the 26 week period ]

Central Contacts

  • François Jacques, Doctor
    819-777-2500
    [email protected]
  • Victorine Sikati Foko, Nurse
    8197772500

Related Studies